0.000USD0.000Pre-market 08/03, 09:30 (ET)
577.22MMarket Cap
LossP/E TTM
Key Figures
13.990Open
14.283High
2.00MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
4.50%Turnover Ratio
14.270Prev. Close
12.790Low
20.25MTurnover
LossP/E Static
2.11P/B
0.00%Div Yield TTM
-20.68%ROA
32.71052wk High
1.20Volume Ratio
-54.76MNet Profit
44.56MShares
-1.3659EPS TTM
--Beta
-22.71%ROE
8.80052wk Low
10.46%Amplitude
59.04%Gross Margin
577.22MMarket Cap
-3.19Reward/Risk
4.60%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Beta Bionics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 39 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.23.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beta Bionics Inc's Score
Support & Resistance

Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Beta Bionics Inc Highlights
StrengthsRisks
Beta Bionics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
33
Thermo Fisher Scientific Inc
TMO
30
Indicators
Financial Indicators
EPS

Relevant data have not been disclosed by the company yet.
Total revenue

Relevant data have not been disclosed by the company yet.
Beta Bionics Inc Info
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Ticker SymbolBBNX
CompanyBeta Bionics Inc
CEOSaint (Sean)
Websitehttps://www.betabionics.com
Shareholders
FAQs
What is the current price of Beta Bionics Inc (BBNX)?
The current price of Beta Bionics Inc (BBNX) is 12.83.
What is the symbol of Beta Bionics Inc?
The ticker symbol of Beta Bionics Inc is BBNX.
What is the 52-week high of Beta Bionics Inc?
The 52-week high of Beta Bionics Inc is 32.71.
What is the 52-week low of Beta Bionics Inc?
The 52-week low of Beta Bionics Inc is 8.80.
What is the market capitalization of Beta Bionics Inc?
The market capitalization of Beta Bionics Inc is 577.22M.
Is Beta Bionics Inc (BBNX) currently rated as Buy, Hold, or Sell?
According to analysts, Beta Bionics Inc (BBNX) has an overall rating of Buy, with a price target of 20.08.
What is the Earnings Per Share (EPS TTM) of Beta Bionics Inc (BBNX)?
The Earnings Per Share (EPS TTM) of Beta Bionics Inc (BBNX) is -1.81.